Scarica l'app Stockscreener
2.16
0.92%
-0.02
Dopo l'orario di chiusura:
2.17
0.010
+0.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.18
Aprire:
$2.27
Volume 24 ore:
4.16M
Relative Volume:
1.85
Capitalizzazione di mercato:
$227.44M
Reddito:
-
Utile/perdita netta:
$-37.34M
Rapporto P/E:
-1.5882
EPS:
-1.36
Flusso di cassa netto:
$-36.91M
1 W Prestazione:
+13.98%
1M Prestazione:
+29.34%
6M Prestazione:
+68.75%
1 anno Prestazione:
+72.80%
Intervallo 1D:
$2.12
$2.29
Intervallo di 1 settimana:
$1.8501
$2.29
Portata 52W:
$0.772
$2.29
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Nome
Sellas Life Sciences Group Inc
Settore
Industria
Telefono
(646) 200-5278
Indirizzo
7 TIMES SQUARE, NEW YORK, NY
Confronta SLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
2.16 | 256.21M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-07-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Iniziato | Oppenheimer | Outperform |
| 2018-04-02 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-19 | Aggiornamento | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
What technical models suggest about SELLAS Life Sciences Group Inc.’s comeback2025 Earnings Impact & High Accuracy Investment Signals - newser.com
Smart tools for monitoring SELLAS Life Sciences Group Inc.’s price actionJuly 2025 Sector Moves & Free Community Supported Trade Ideas - newser.com
How institutional ownership impacts SELLAS Life Sciences Group Inc. stockEarnings Growth Report & Expert-Curated Trade Recommendations - newser.com
How SELLAS Life Sciences Group Inc. stock valuations compare to rivalsPortfolio Return Summary & Precise Entry and Exit Recommendations - newser.com
Can SELLAS Life Sciences Group Inc. stock sustain revenue growth2025 Geopolitical Influence & Low Risk Entry Point Tips - newser.com
Published on: 2025-10-15 04:42:51 - newser.com
How to recover losses in SELLAS Life Sciences Group Inc. stockMarket Activity Summary & Daily Profit Maximizing Trade Tips - newser.com
Quantitative breakdown of SELLAS Life Sciences Group Inc. recent move2025 Volume Leaders & Low Risk High Win Rate Stock Picks - newser.com
How to build a custom watchlist for SELLAS Life Sciences Group Inc.2025 Support & Resistance & Weekly Momentum Picks - newser.com
SELLAS Life Sciences to Present In Vivo Preclinical Data - GlobeNewswire
SELLAS to present CDK9 inhibitor data for T-cell leukemia at ESMO - Investing.com India
Biotech Stocks Surge After Hours On Trial Updates, Data Momentum - Nasdaq
SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment - Stocktwits
What analyst consensus says on SELLAS Life Sciences Group Inc. stockChart Signals & Risk Managed Investment Signals - newser.com
Using R and stats models for SELLAS Life Sciences Group Inc. forecastingTrade Signal Summary & Capital Efficient Trading Techniques - newser.com
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 - GlobeNewswire
SELLAS Life Sciences Group, Inc. to Present in Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia AAt the European Society for Medical Oncology Congress 2025 - MarketScreener
What data driven models say about SELLAS Life Sciences Group Inc.’s futureMarket Trend Review & Weekly Momentum Stock Picks - newser.com
Using data models to predict SELLAS Life Sciences Group Inc. stock movementJuly 2025 Decliners & Precise Entry and Exit Recommendations - newser.com
How to integrate SELLAS Life Sciences Group Inc. into portfolio analysis toolsPortfolio Performance Report & High Return Trade Guides - newser.com
Published on: 2025-10-09 03:27:21 - newser.com
Published on: 2025-10-09 03:07:14 - newser.com
Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth? - Sahm
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Significant Decrease in Short Interest - Defense World
Multi factor analysis applied to SELLAS Life Sciences Group Inc.July 2025 Momentum & Stepwise Entry/Exit Trade Alerts - newser.com
Using Python tools to backtest SELLAS Life Sciences Group Inc. strategies2025 Dividend Review & Free Accurate Trade Setup Notifications - newser.com
Can SELLAS Life Sciences Group Inc. (RXK3) stock double in coming years2025 Short Interest & Stock Market Timing Techniques - newser.com
Published on: 2025-10-06 05:59:31 - newser.com
SELLAS Extends Times Square Sublease Agreement - TipRanks
Why SELLAS Life Sciences Group Inc. (RXK3) stock benefits from AI revolutionEarnings Risk Summary & Community Consensus Picks - newser.com
Published on: 2025-10-03 03:10:59 - newser.com
Chart based analysis of SELLAS Life Sciences Group Inc. trendsJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
Sellas Life Sciences Group Inc Azioni (SLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sellas Life Sciences Group Inc Azioni (SLS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wasman Jane | Director |
May 30 '25 |
Buy |
1.69 |
20,000 |
33,800 |
30,400 |
| Kalin Katherine Bach | Director |
May 22 '25 |
Buy |
1.80 |
20,000 |
36,000 |
41,000 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):